|
ハセガワ タイジ
HASEGAWA Taiji
長谷川 泰司 所属 医学部 医学科（東京女子医科大学病院） 職種 講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study. |
| 掲載誌名 | 正式名：Japanese journal of ophthalmology 略 称：Jpn J Ophthalmol ISSNコード：16132246/00215155 |
| 掲載区分 | 国内 |
| 巻・号・頁 | 64(4),pp.338-345 |
| 著者・共著者 | Koizumi Hideki, Yamamoto Akiko, Ogasawara Masashi, Maruko Ichiro, Hasegawa Taiji, Itagaki Kanako, Sekiryu Tetsuju, Okada Annabelle A, Iida Tomohiro |
| 発行年月 | 2020/07 |
| 概要 | PURPOSE:To evaluate the development and rate of growth in macular atrophy after intravitreal injections of aflibercept (IVAs) for neovascular age-related macular degeneration (AMD) over a 2-year period.STUDY DESIGN:Retrospective, interventional, consecutive case series.METHODS:This study included 94 eyes of 92 patients with treatment-naïve AMD involving the foveal center treated with IVAs at 3 university hospitals in Japan. The patients underwent IVAs bimonthly after 3 initial monthly doses in the first year. The protocol was converted to a treat-and-extend regimen in the second year. The incidence and growth rate of macular atrophy were quantified based on hypoautofluorescence detected by fundus autofluorescence images. Additionally, possible background factors related to the development and rate of growth of macular atrophy were investigated.RESULTS:Of 94 eyes, 39 (41.5%) had typical AMD and 55 (58.5%) had polypoidal choroidal vasculopathy. Ten eyes (10.6%) had macular atrophy at the baseline. Of the remaining 84 eyes, 14 (16.7%) had developed new macular atrophy at 2 years, the square root of the growth rate of atrophy was 0.52 mm/year. In multivariate analyses, a poorer best-corrected visual acuity (P = 0.01) and the presence of intraretinal fluid (P = 0.04) at baseline were found to be the independent predictors for the development of macular atrophy. No factors were found that were significantly related to the growth rate of the macular atrophy.CONCLUSIONS:Our study determined the incidence and rate of growth of macular atrophy after IVAs for neovascular AMD in clinical settings. Eyes with vision reduction and intraretinal fluid at the baseline develop macular atrophy more frequently after IVAs for neovascular AMD. |
| DOI | 10.1007/s10384-020-00745-0 |
| PMID | 32447586 |